Medicine
LumaSon 0.19 mg/0.19 mg/60.7 mg per mg powder for injectable suspension
LumaSon 0.19 mg/0.19 mg/60.7 mg per mg powder for injectable suspension is a prescription medicine containing Distearoylphosphatidylcholine, dl-, Sodium 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) and Sulfur hexafluoride for intravenous, intravesical use, marketed by Bracco Diagnostics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store the kit at 25°C (77°F), excursions permitted to 15-30°C (59-86°F).
Key facts
- Active ingredient (INN)
- Distearoylphosphatidylcholine, dl-, Sodium 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) and Sulfur hexafluoride
- Brand
- LumaSon
- Strength
- 0.19 mg/0.19 mg/60.7 mg per mg
- Dosage form
- Powder for injectable suspension
- Route
- Intravenous, intravesical
- Packs
- 20 vials
- Marketing authorisation holder
- Bracco Diagnostics
- Manufacturer
- Bracco Diagnostics
- Origin register
- US FDA, United States
- Storage
- Store the kit at 25°C (77°F), excursions permitted to 15-30°C (59-86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 April 2021
- Identifiers
- DailyMed set ID 69822a55-226c-f133-e3b8-2b5826667c5b, 7c679424-c3f7-ed02-892f-20ca0d775089NDC 0270-7097Application NDA203684
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 20 vial in 1 box / 25 mg in 1 vial | 0270-7097-07 | Bracco Diagnostics | 1 April 2021 |
| 20 vial in 1 box / 25 mg in 1 vial | 0270-7097-08 | Bracco Diagnostics | 1 April 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Distearoylphosphatidylcholine, dl-, Sodium 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) and Sulfur hexafluoride is a fixed-dose combination medicine. It is available as powder for injectable suspension for intravenous and intravesical use. MedsAcross supplies Distearoylphosphatidylcholine, dl-, Sodium 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) and Sulfur hexafluoride for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Distearoylphosphatidylcholine, dl-, Sodium 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) and Sulfur hexafluorideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LumaSon prescribing information (Bracco Diagnostics) · U.S. National Library of Medicine, DailyMed
Need LumaSon 0.19 mg/0.19 mg/60.7 mg per mg powder for injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.